We’ve been talking a lot lately about bacterial resistance to drugs, most specifically as bacteria approach the limits of our treatments of last resort. As a consequence of the diminishing returns on traditional families of antibiotics, scientists have turned their focus to more novel approaches for combating infection. The work has been aimed at better understanding the interaction between our immune system and particular bacterial strains. Most recently, a team of researchers at the University of Washington have discovered just how the common staph infection resists our defenses.

Humans are in an escalating battle with bacterial infections. Our last lines of antibiotic defense are increasingly becoming our only lines. Bacteria have demonstrated an adept ability to mutate and foil drugs at a pace which nearly bests our research and development efforts. However, a new class of molecules recently synthesized by researchers at Stanford University is
showing early promise in fighting off infection in a manner unlike any other.